1. United Kingdom Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Tristel Plc

Tristel Plc

4.54
EUR
0.00
(0.00%)
217.32MMarket Cap
Feb 22Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.26
0.34
0.38
0.41
0.48
0.52
0.59
0.71
0.67
0.66
0.76
0.88
0.97
- -
Basic EPS, GAAP
-0.03
0.03
0.05
0.05
0.08
0.08
0.09
0.11
0.08
0.02
0.09
0.14
0.14
- -
Free Cash Flow per Basic Share
0.01
0.05
0.04
0.09
0.08
0.07
0.09
0.1
0.11
0.09
0.13
0.18
0.17
- -
Dividend per Share
- -
0.01
0.02
0.06
0.07
0.04
0.05
0.06
0.06
0.07
0.1
0.13
0.14
- -
Book Value per Share
0.28
0.3
0.34
0.35
0.38
0.43
0.52
0.63
0.67
0.63
0.65
0.68
0.69
0.7
Tangible Book Value per Share
0.12
0.15
0.19
0.21
0.21
0.27
0.24
0.34
0.41
0.43
0.44
0.47
0.48
0.5
Basic Weighted Avg Shares
40
40
41
42
42
43
44
45
47
47
47
47
48
48
Sales/Revenue/Turnover
11
13
15
17
20
22
26
32
31
31
36
42
46
- -
Operating Margin (%)
4.67
13.5
16.57
15.01
19.25
17.91
18.2
21.48
15.36
5.62
14.67
16.65
21
- -
Depreciation Expense
1
1
1
1
1
1
1
2
3
3
3
3
3
- -
Net Income, GAAP
-1
1
2
2
3
3
4
5
4
1
4
6
7
- -
Effective Tax Rate (%)
- -
30.22
13.21
18.94
13.84
18.32
15.07
23.18
2.79
36.53
12.73
8.37
21.1
- -
Profit Margin (%)
-11.97
9.64
14.45
12.29
16.85
14.73
15.4
16.1
11.79
3.17
12.39
15.47
14.29
- -
Working Capital
3
5
7
8
7
9
8
11
13
16
17
18
19
20
LT Debt
- -
- -
- -
- -
- -
- -
- -
5
5
5
4
5
5
5
Total Equity
11
12
14
15
16
18
23
28
31
30
31
32
33
34
Return on Invested Capital (%)
- -
10.52
15.92
13.39
20.28
17.79
18.09
17.28
12.6
3.01
12.66
16.86
16.72
- -
Return on Capital (%)
- -
11.51
16.91
14.43
22.03
18.97
19.3
18.08
10.66
3.04
12.94
18.04
17.74
- -
Return on Common Equity (%)
-10.74
11.16
16.78
14.44
22.04
18.98
19.3
19.69
12.21
3.23
14.78
20.57
20.31
- -

Capital Structure

GBP

•

in mil. unless spec.
Dec'25
Jun'25
Dec'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
5
5
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
48
48
48
Market Capitalization
196
191
190

Working Capital

GBP

•

in mil. unless spec.
Dec'25
Jun'25
Dec'26
Total Current Assets
23
26
26
Cash, Cash Equivalents & STI
12
13
13
Accounts Receivable, Net
7
6
8
Inventories
5
5
4
Total Current Liabilities
6
7
6
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.2%
3.13%
1.79%
Free Cash Flow
24.02%
14.76%
-4.25%
Net Income, GAAP
40.14%
59.69%
2.33%
Sales/Revenue/Turnover
11.97%
8.24%
10.8%
Total Cash Common Dividend
36.87%
21.69%
6.97%

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
42
2025
- -
- -
46
2026
- -
- -
- -

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.14
2025
- -
- -
0.14
2026
- -
- -
- -

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.13
2025
- -
- -
0.14
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Christopher Paul Lee
Full Time Employees
267
Sector
Health technology
Industry
Medical specialties
Address
Lynx Business Park Cambridgeshire EA United Kingdom CB8 7NY
IPO Date
Jun 1, 2005
Website
tristel.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Tristel plc Tristel plc is a United Kingdom-based infection prevention company that manufactures and sells chlorine dioxide-based products for hospital medical device decontamination under the Tristel brand and sporicidal environmental surface disinfection under the Cache brand; its medical device portfolio includes high-level disinfectants such as Tristel Duo ULT, Tristel OPH for ophthalmic devices, and solutions for airway management, cardiology, ear/nose/throat, endoscopy, ophthalmology, ultrasound, urology, and women's health applications, while Cache products target critical care surfaces as a sustainable alternative to pre-wetted wipes; other offerings encompass Crystel contamination control disinfectants for cleanrooms, laboratories, and pharmaceuticals, Anistel airborne and veterinary disinfectants, and the 3T digital platform for training, traceability, and compliance. Founded in 1993 and headquartered in Snailwell near Cambridge, the company operates 20 subsidiaries across Europe (including Germany, France, Italy, Belgium, Netherlands, Austria, Switzerland, Poland, and new entries in Spain), Australia, New Zealand, Asia (Malaysia, Singapore, Hong Kong, China, India), the Middle East, and the United States, employing around 270 people and selling into over 40 countries primarily to hospitals via direct sales and distributors. Recent developments include FDA clearance for Tristel OPH in May 2025 enabling US ophthalmic market entry, partnership expansion with Parker Laboratories driving North American royalty income growth to £108k, launch of Tristel VISICLEAN colored cleaning foam and Cache Tank surface products post-year-end, insourcing of Trio Wipes manufacturing for £0.8m annual savings, a multi-year NHS Supply Chain contract supporting UK pricing uplift, direct subsidiaries established in Spain, India, and Austria, appointment of Anna Wasyl as CFO and Matt Sassone as CEO following Paul Swinney's retirement, and grant of LTIP options to executives in November 2025, alongside record FY2025 revenue of £46.5m up 11%, adjusted pre-tax profit of £10.1m up 23%, and debt-free cash balances of £12.8m.

Company News

Company News APIChatGPT